H8K-MC-JZAO(a) SUMMIT-1
Laufzeit: 01.01.2010 - 31.12.2012
Kurzfassung
A Randomized Phase 3 Study of Tasisulam Administered as an Intravenous Infusion on DAy 1 of a 28-Day Cycle vx. Paclitaxel as Second-Line Treatment in Patients with Metastatic Melanoma
